Literature DB >> 11299312

Mechanisms of inverse agonism of antipsychotic drugs at the D(2) dopamine receptor: use of a mutant D(2) dopamine receptor that adopts the activated conformation.

J Wilson1, H Lin, D Fu, J A Javitch, P G Strange.   

Abstract

The antipsychotic drugs have been shown to be inverse agonists at the D(2) dopamine receptor. We have examined the mechanism of this inverse agonism by making mutations in residue T343 in the base of the sixth transmembrane spanning region of the receptor. T343R, T343S and T343K mutant D(2) dopamine receptors were made and the T343R mutant characterized in detail. The T343R mutant D(2) dopamine receptor exhibits properties of a receptor that resides more in the activated state, namely increased agonist binding affinity (independent of G-protein coupling and dependent on agonist efficacy), increased agonist potency in functional tests (adenylyl cyclase inhibition) and increased inverse agonist effects. The binding of agonists to the mutant receptor also shows sensitivity to sodium ions, unlike the native receptor, so that isomerization of the receptor to its inactive state may be driven by sodium ions. The binding of inverse agonists to the receptor is, however, unaffected by the mutation. We conclude that inverse agonism at this receptor is not achieved by the inverse agonist binding preferentially to the non-activated state of the receptor over the activated state. Rather the inverse agonist appears to bind to all forms of the receptor but then renders the receptor inactive.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11299312     DOI: 10.1046/j.1471-4159.2001.00233.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  13 in total

1.  Differential dynamics in the G protein-coupled receptor rhodopsin revealed by solution NMR.

Authors:  Judith Klein-Seetharaman; Naveena V K Yanamala; Fathima Javeed; Philip J Reeves; Elena V Getmanova; Michele C Loewen; Harald Schwalbe; H Gobind Khorana
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-27       Impact factor: 11.205

2.  Mechanisms of inverse agonist action at D2 dopamine receptors.

Authors:  David J Roberts; Philip G Strange
Journal:  Br J Pharmacol       Date:  2005-05       Impact factor: 8.739

Review 3.  Agonist binding, agonist affinity and agonist efficacy at G protein-coupled receptors.

Authors:  P G Strange
Journal:  Br J Pharmacol       Date:  2008-01-28       Impact factor: 8.739

4.  Differential profile of typical, atypical and third generation antipsychotics at human 5-HT7a receptors coupled to adenylyl cyclase: detection of agonist and inverse agonist properties.

Authors:  Isabelle Rauly-Lestienne; Elisa Boutet-Robinet; Marie-Christine Ailhaud; Adrian Newman-Tancredi; Didier Cussac
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-09-05       Impact factor: 3.000

Review 5.  Agonist high- and low-affinity states of dopamine D₂ receptors: methods of detection and clinical implications.

Authors:  Jan-Peter van Wieringen; Jan Booij; Vladimir Shalgunov; Philip Elsinga; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-12-09       Impact factor: 3.000

6.  Assays for enhanced activity of low efficacy partial agonists at the D(2) dopamine receptor.

Authors:  H Lin; S G N Saisch; P G Strange
Journal:  Br J Pharmacol       Date:  2006-08-21       Impact factor: 8.739

Review 7.  Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism.

Authors:  Georges Vauquelin; Sophie Bostoen; Patrick Vanderheyden; Philip Seeman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-02-14       Impact factor: 3.000

8.  Recruitment of beta-arrestin2 to the dopamine D2 receptor: insights into anti-psychotic and anti-parkinsonian drug receptor signaling.

Authors:  Ib V Klewe; Søren M Nielsen; Louise Tarpø; Eneko Urizar; Concetta Dipace; Jonathan A Javitch; Ulrik Gether; Jan Egebjerg; Kenneth V Christensen
Journal:  Neuropharmacology       Date:  2008-04-08       Impact factor: 5.250

9.  Effects of Delta9-tetrahydrocannabivarin on [35S]GTPgammaS binding in mouse brain cerebellum and piriform cortex membranes.

Authors:  I Dennis; B J Whalley; G J Stephens
Journal:  Br J Pharmacol       Date:  2008-05-19       Impact factor: 8.739

10.  Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation.

Authors:  Yang Han; Irina S Moreira; Eneko Urizar; Harel Weinstein; Jonathan A Javitch
Journal:  Nat Chem Biol       Date:  2009-08-02       Impact factor: 15.040

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.